Georgios S. Limouris

Author

Also Known As

G Limouris, G S Limouris, G. LIMOURIS, G. Limouris, G. S. Limouris, GEORGIOS S. LIMOURIS, Georgios Limouris, Georgios S Limouris, Georgios S. Limouris, Georgios Spyridon Limouris

Publications

422

Citations

H-Index

Concepts

All Affiliations

Aretaeio Hospital 401 General Military Hospital of Athens

About

Georgios S. Limouris is an author at Aretaeio Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	235
2	Health Sciences	4	4	150
3	Engineering	2	2	42
4	Social Sciences	1	1	24
5	Cell Biology	1	1	26

Georgios S. Limouris

Publications

356

Citations

H-Index

Page 1

	Year	Citations
Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases Georgios S. Limouris, Achilles Chatziioannou, Dimitrios C. Kontogeorgakos, European Journal of Nuclear Medicine and Molecular Imaging HepatologyNeuroendocrine Liver MetastasesLiver PhysiologyHepatobiliary TumorPathology	2008	68
Imaging and localization of pancreatic insulinomas Achilles Chatziioannou, Dimitrios Kehagias, D Mourikis, Clinical Imaging Medical ImagingPancreatic Fluid CollectionPancreatic InsulinomasHistopathologyPathology	2001	54
Clinical and imaging correlations of bone turnover markers in prostate cancer patients with bone only metastases Athanasios Zafeirakis, Georgios Papatheodorou, Georgios S. Limouris Nuclear Medicine Communications	2010	27
Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors. Georgios S. Limouris, V. Giannakopoulos, A. Stavraka, PubMed I-123 MlbgEngineeringTumor InnervationDmsa UptakePathology	1997	26
Severe dopaminergic pathways damage in a case of chronic toluene abuse Sokratis G. Papageorgiou, Evgenia Karantoni, Dionysios Pandis, Clinical Neurology and Neurosurgery Substance AbusePsychoactive DrugPsychiatryAddictionMedicine	2009	24
Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors. Georgios S. Limouris, Ioannis Karfis, A Chatzioannou, PubMed	2012	22
Evaluation of the Therapeutic Response to In-111-DTPA Octreotide-Based Targeted Therapy in Liver Metastatic Neuroendocrine Tumors According to CT/MRI/US Findings Georgios S. Limouris, Dimitrios C. Kontogeorgakos, Georgios Papanikolos, Cancer Biotherapy and Radiopharmaceuticals	2005	20
Patient-specific dosimetry calculations using mathematic models of different anatomic sizes during therapy with 111In-DTPA-D-Phe1-octreotide infusions after catheterization of the hepatic artery. Dimitrios K. Kontogeorgakos, P. Dimitriou, Georgios S. Limouris, PubMed	2006	20
Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases Athanasios Zafeirakis, Georgios Papatheodorou, Athanasios Arhontakis, European Journal of Nuclear Medicine and Molecular Imaging Bone Turnover MarkersPainful Osseous MetastasesUrologyGenitourinary CancerMedicine	2009	19
Comparison of 111In-[DTPA0]Octreotide Versus Non Carrier Added 177Lu- [DOTA0,Tyr3]-Octreotate Efficacy in Patients With GEP-NET Treated Intra-arterially for Liver Metastases Georgios S. Limouris, V. Poulantzas, N. Trompoukis, Clinical Nuclear Medicine	2015	18

Page 1